In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Blood pressure monitor guidelines

This article was originally published in The Gray Sheet

Executive Summary

Central (or aortic) pulse pressure, which can be measured noninvasively with Omron Healthcare's HEM-9000AI monitor, is added to the list of blood pressure indicators in the new European Society of Hypertension/European Society of Cardiology 1guidelines for managing hypertension. The guidelines, released in June, note that the prognostic role of the Omron approach, which estimates aortic blood pressure based on a reading from a peripheral artery, still "needs to be further confirmed in more large-scale observational and interventional studies" before it drives physician practice. HEM-9000AI has been available in the United States since 2006 and in Japan, where the firm is based, since 2005. Omron plans to launch the device in Europe and other parts of Asia in the near future...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel